Patents Assigned to BioMarin Pharmaceuticals
  • Methods for diagnosing atherosclerosis by measuring endogenous heparin and methods for treating atherosclerosis using heparin
    Patent number: 6291439
    Abstract: The present invention provides methods for measuring endogenous heparin in a mammal at levels that were previously undetectable. The present invention further features methods for assessing the risk for and assessing the progression of atherosclerosis and methods for treating or inhibiting the progression of atherosclerosis. The invention also features methods for monitoring plasma heparin levels in subjects undergoing heparin treatment. Additionally, the present invention provides kits for assaying for heparin in biological samples.
    Type: Grant
    Filed: September 2, 1998
    Date of Patent: September 18, 2001
    Assignee: BioMarin Pharmaceuticals
    Inventor: John C. Klock
  • Chondroitin sulfate as a marker of bone resorption
    Patent number: 6287789
    Abstract: The subject invention provides methods and kits for detecting increased bone resorption in patients. These methods and kits use chondroitin sulfate, a glycosaminoglycan, as a marker for bone resorption. Levels of chondroitin sulfate are detected in samples of urine or serum taken from patients. Measurements of chondroitin sulfate levels are made by methods such as fluorophore-assisted carbohydrate electrophoresis (FACE). Knowledge of increased bone resorption rates is useful in diagnosis of bone disorders such as osteoporosis.
    Type: Grant
    Filed: February 8, 1999
    Date of Patent: September 11, 2001
    Assignee: BioMarin Pharmaceuticals
    Inventor: John C. Klock